Bronchogen
Bronchogen (Khavinson)
Bronchogen is a synthetic tripeptide bioregulator (Ala-Glu-Asp) developed by Professor Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology. It belongs to the Khavinson peptide bioregulator class, which are short peptides designed to target specific tissues. Bronchogen is designed to act on bronchial and lung tissue, supporting respiratory epithelial function and mucosal integrity.
Starting dose. 500 mcg — Daily
SubQ injection, any time of day. 10-20 day courses, 2-3 cycles per year with 4-6 months between courses (Khavinson protocol). Pin alone or with other bioregulators only.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
How it works
Proposed to interact with DNA regulatory sequences in bronchial epithelial cells, modulating gene expression related to tissue repair and mucosal defense.
May upregulate synthesis of surfactant proteins and mucins that maintain airway surface integrity and immune barrier function.
Theorized to normalize peptide regulation in aged or damaged lung tissue, restoring protein synthesis patterns characteristic of younger, healthier tissue.
What to expect
Days 1-7: Minimal perceptible effects. Cellular-level changes in bronchial tissue may be occurring but are not typically felt.
Evidence
Claims we could not support
No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.
Dose/route: 500 mcg SubQ daily; “Start ~40 days”; advanced 1 mg on 6-on/1-off. No checked PubMed abstract administered the page-defined Bronchogen molecule subcutaneously at this dose, frequency, or course length.
Mechanism/identity: tripeptide Ala-Glu-Asp regulating bronchial epithelial DNA/gene expression. Exact-name PubMed abstracts define Bronchogen as a tetrapeptide (Ala-Glu-Asp-Leu, with one abstract printing Ala-Asp-Glu-Leu), not the page’s tripeptide Ala-Glu-Asp. Because the molecular identity does not match, those gene-expression and lung-model papers were not transferred to this card.
Primary safety concern / tolerability for SubQ use. No checked human abstract established safety or tolerability for subcutaneous Bronchogen at the displayed regimen.
Interactions & stacking
Two different questions: what is documented about running these together, and what is documented about drawing them into the same syringe. A good pharmacological partner can still have to be pinned separately.
Keep separate
Check any specific pair in the Stack & Interaction Checker, which answers both questions separately. Absence of a documented conflict is not evidence of safety.
Pharmacokinetics
Minutes (tiny peptide)
SubQ
SubQ
Days to weeks (gene expression changes in bronchial tissue persist long after peptide clearance)
Rapid enzymatic degradation (peptidases); renal excretion of amino acid components
Storage. Store refrigerated at 2-8C.
Regulatory status
Unregulated research peptide. Not approved by FDA, EMA, or other major regulatory bodies. Used primarily within the Khavinson bioregulator framework in Russia and by integrative medicine practitioners.
Put it to work
Calculate, log & track
Open Bronchogen straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open Bronchogen in the app →Go deeper
The guide & community
The complete Bronchogen walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗